1011386
ClinicalTrials.gov NCT03633227
Research payments
$224,976
Through program year 2020, $224,976 in research payments was reported against 1011386, across 80 payments, paid by Intercept Pharmaceuticals, Inc..
- Paid by
- Intercept Pharmaceuticals, Inc.
- ClinicalTrials.gov
- NCT03633227
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2020 | Research | $98,191 | 49 |
| 2019 | Research | $126,785 | 31 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- John Vierling Houston, TX Named on 18 payments
- Christopher Bowlus Sacramento, CA Named on 11 payments
- Bradley Freilich Kansas City, MO Named on 9 payments
- Paul Thuluvath Baltimore, MD Named on 7 payments
- Eric Lawitz San Antonio, TX Named on 7 payments
- Ashwini Mehta Dallas, TX Named on 6 payments
- Frederick Askari Ann Arbor, MI Named on 5 payments
- Parvez Mantry Dallas, TX Named on 4 payments
- Khalid Mumtaz Columbus, OH Named on 3 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.